Celldex Therapeutics Announces Upcoming Presentation At The Leerink Swann Rare Disease Roundtable

PHILLIPSBURG, N.J., Sept. 26, 2013 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, and Tibor Keler, PhD, Senior Vice President and Chief Scientific Officer, will present at the Leerink Swann Rare Disease Roundtable on Wednesday, October 2, 2013 at 3:20 p.m. ET at the Le Parker Meridien in New York City.

A live webcast of the presentation will be available online on the " Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay of the presentation will be available for 30 days following the event.

About Celldex Therapeutics, Inc.

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldextherapeutics.com .
CONTACT: Sarah Cavanaugh         Vice President of Investor Relations &         Corp Communications         Celldex Therapeutics, Inc.         (781) 433-3161         scavanaugh@celldextherapeutics.com

If you liked this article you might like

Melinta Up After Deal for Medicines' Infectious Disease Unit -- Biotech Movers

Melinta Up After Deal for Medicines' Infectious Disease Unit -- Biotech Movers

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Stock Up on Q2 Results